Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
German drugmaker Stada Arzneimittel has appointed Wolfgang Ollig as group chief financial officer (CFO) with effect from February 1, 2020. 31 January 2020
On the day that the UK leaves the European Union (EU), the European Medicines Agency (EMA) has reminded drugmakers that any major changes will not be seen for another 11 months. 31 January 2020
At its January meeting, the European Medicines Agency’s Committee for Medicinal Products for Human USE (CHMP) recommended approval of eight novel medicines and one biosimilar. The final decision of the European Commission on the marketing authorization is expected in the coming months. 31 January 2020
finnCap, an adviser and broker to ambitious growth companies, has released a new report showing the extent to which healthcare companies can benefit from employing artificial intelligence (AI). 31 January 2020
In 2020, the national regime regarding the procurement of goods, work, services does not apply to products from the EAEU countries (Belarus, Kazakhstan, Armenia, Kyrgyzstan), states a press release from the Association of The Russian Pharmaceutical Producers. 31 January 2020
Results from the pre-planned final overall survival analysis of the Phase III ARAMIS (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) trial that investigated Nubeqa (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) show a significant improvement in overall survival (OS) in patients receiving Nubeqa plus androgen deprivation therapy (ADT) compared to placebo plus ADT. 31 January 2020
A better-than-forecast financial results statement has sent Eli Lilly stock climbing nearly 1.5% in pre-market trading. Shares were already up 0.47% after strong trading on Wednesday. 30 January 2020
East Coast, USA-based Spring Bank Pharmaceuticals has stopped work on inarigivir soproxil, a Phase II candidate under testing in chronic hepatitis B virus (HBV). 30 January 2020
Looking at the deals announced in the fourth quarter of 2019, the M&A landscape was dominated by large pharma but increasingly biopharma companies and generic manufacturers are expanding their product portfolios and services through M&A activities, too. 30 January 2020
Texas, USA-based Vizient has released its Winter 2020 Drug Price Forecast projecting that health systems, including inpatient and non-acute environments, can expect a 3.59% increase for pharmaceutical purchases made from July 1 to June 30, 2021. 30 January 2020
Spanish drugmaker PharmaMar’s shares rose as much as 6.3% to 4.23 euros this morning, after it announced receipt of the upfront payment of $200 million from the agreement signed with Jazz Pharmaceuticals. 29 January 2020
Shares of Swiss pharma giant Novartis were up 1.48% at 93.96 Swiss Francs by mid-morning today, as it posted fourth-quarter and full year 2019 results and a positive outlook for the coming year. 29 January 2020
UK cancer patients have had to wait longer for innovative new cancer drugs than for more conventional treatments, pointing to a failure to successfully fast track these exciting drugs, according to a new analysis. 29 January 2020
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued draft guidance not to recommend Spravato (esketamine) nasal spray. 28 January 2020
Ahead of the opening bell, shares in New York-based drug giant Pfizer were off a hefty 1.5% on Tuesday, as the firm announced a disappointing quarterly profit result, below analysts’ expectations. 28 January 2020